UPDATE: H.C. Wainwright Starts Ekso Bionics (EKSO) at Buy

(updated comment)

H.C. Wainwright analyst Swayampakula Ramakanth initiates coverage on Ekso Bionics (NASDAQ: EKSO) with a Buy rating and a price target of $1.20.

The analyst comments "Ekso Bionics develops and markets robotic exoskeletons for medical and industrial purposes. Its EksoHealth division markets Ekso GT, a device used for rehabilitation of patients who suffered a stroke or a spinal cord injury (SCI), and records 78% of Ekso revenues. The EksoWorks division markets robotics to improve endurance, strength, and safety of industrial workers. EksoHealth is the primary focus of management as they continue to refine their business strategy to ensure sustained growth. We project Ekso's total revenues to grow to $155M by 2030 from $15M in 2019, with 89% coming from EksoHealth."

For an analyst ratings summary and ratings history on Ekso Bionics click here. For more ratings news on Ekso Bionics click here.

Shares of Ekso Bionics closed at $0.59 yesterday.

You May Also Be Interested In

• UPDATE: Jefferies Upgrades Booking Holdings (BKNG) to Buy 'as Travel Rebounds in 2H21'
• Truist Securities Starts Instil Bio Inc (TIL) at Buy
• B.Riley Starts Identiv, Inc. (INVE) at Buy